KRRO-110

Soleno Therapeutics maintains robust financial standing with $318.6 million in cash reserves as they await FDA review of DCCR for Prader-Willi Syndrome treatment.

Wave Life Sciences achieves first-ever RNA editing results in humans for alpha-1 antitrypsin deficiency, demonstrating therapeutic protein level increases with a single dose treatment.

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Arbor Biotechnologies' ABO-101, a CRISPR-based gene editing therapy, has been cleared by the FDA for a Phase 1/2 clinical trial in primary hyperoxaluria type 1 (PH1).

Korro Bio has received approval to begin a Phase I/IIa trial in Australia for KRRO-110, an RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).